AnaptysBio Inc. (NASDAQ: ANAB) reported positive results for its phase 2a clinical trial of its antibody, ANB020, which is used in adult patients with moderate to severe atopic dermatitis. AnaptysBio shares skyrocketed over 80 percent midday on Tuesday after the announcement.
Atopic dermatitis is also the medical term for eczema, which is a skin irritation that usually develops early on in the patient's’ childhood years. Moderate cases can simply be just itching around the face, but severe cases can spread around the body and can affect everyday tasks.
In the trial, after a single dose of the AB020, 75 percent of the patients in the test reported a 50 percent improvement on the Eczema Area Severity Index (EASI) relative to the enrollment baseline. The antibody drug was well tolerated among the patients.
The average baseline EASI score upon enrollment was 32. At day 29, 10 of 12 patients (83 percent) achieved EASI-50, of which four patients (33 percent) also achieved EASI-75. Then by day 57, nine out of 12 patients (75 percent) achieved EASI-50, of which five patients (42 percent) also achieved EASI-75
“We are very encouraged by the efficacy results to date in this Phase 2a study, which exemplify our strategic focus on developing first-in-class anti-inflammatory antibody therapeutics to help patients suffering from debilitating inflammatory diseases,” said Hamza Suria, president and chief executive officer of AnaptysBio.
“The rapid and sustained benefit observed in patients after a single dose of ANB020 is an encouraging interim result from this trial. I look forward to the continued development of ANB020 as a potential future therapeutic option for patients suffering from this disease.” said Dr. Graham Ogg, primary investigator of the Phase 2a study.
The phase 2a trial is still ongoing and patients will be assessed again in 140 days from enrollment date.
During the first half of 2018, the company plans to randomize Phase 2b in a double blinded and placebo controlled study among 200-300 adult patients. Data is expected to be reported in 2019.